| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said AppLovin Corporation (NASDAQ:APP) is the number one performing large cap stock of the year so far.
On April 16, Morgan Stanley analyst Matthew Cost maintained AppLovin with an Equal-Weight rating and raised the price target from $55 to $70.
Stephanie Link of Hightower said she likes Freeport-McMoRan Inc. (NYSE:FCX) amid recovery in China.
On April 9, BofA Securities analyst Lawson Winder upgraded Freeport-McMoRan from Neutral to Buy and announced a $59 price target, while Scotiabank analyst Orest Wowkodaw maintained the stock with a Sector Outperform and raised the price target from $48 to $55.
Freeport-McMoRan is a top holding in the broader SPDR S&P Metals & Mining ETF (NYSE:XME).
Don’t forget to check out our premarket coverage here
Jim Lebenthal of Cerity Partners named CVS Health Corporation (NYSE:CVS), which is set to report quarterly earnings soon.
CVS Health is scheduled to hold a conference call with analysts and investors on May 1 to discuss first quarter 2024 financial results. Analysts expect the company to report quarterly earnings at $1.71 per share, down from $2.2 per share in the year-ago period. The company is projected to post quarterly revenue of $89.21 billion, up from $80.81 billion in the year-earlier quarter.
Check This Out: Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
